Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Tesofensine | Tirzepatide | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | Research indicates 0.25-0.5 mg daily via oral administration. | — |
| Timing | Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia. | — |
| Cycle Duration | 12-24 week cycles. Monitor cardiovascular parameters throughout. | — |
| Evidence Level | moderate_human | Strong (FDA-approved) |
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor with affinity for dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters. It suppresses appetite through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, reflecting additive effects of increased NE and DA activity. Tesofensine is a dual-action drug with both anorexigenic properties (appetite suppression) and metabolic properties (increased energy expenditure), silencing GABAergic hypothalamic neurons in the lateral hypothalamus.
Research indicates 0.25-0.5 mg daily via oral administration.
Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia.
12-24 week cycles. Monitor cardiovascular parameters throughout.
Dual GIP/GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, slows gastric emptying, and acts on hypothalamic appetite centers. Produces greater weight loss than semaglutide in head-to-head trials. Also improves cardiovascular risk markers.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →